What is HC Wainwright's Estimate for BioNTech Q4 Earnings?

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Investment analysts at HC Wainwright dropped their Q4 2026 earnings per share (EPS) estimates for shares of BioNTech in a report issued on Monday, June 16th. HC Wainwright analyst R. Burns now expects that the company will post earnings of $0.88 per share for the quarter, down from their prior forecast of $0.90. HC Wainwright currently has a "Buy" rating and a $138.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share.

Several other brokerages have also issued reports on BNTX. Truist Financial reissued a "buy" rating and set a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Morgan Stanley reduced their target price on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Citigroup reaffirmed a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. The Goldman Sachs Group assumed coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target on the stock. Finally, Canaccord Genuity Group restated a "buy" rating and set a $171.44 price objective on shares of BioNTech in a report on Tuesday, March 11th. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $137.86.

BioNTech Trading Up 2.0%

Shares of BNTX stock traded up $2.13 during trading hours on Tuesday, hitting $106.53. 721,497 shares of the company were exchanged, compared to its average volume of 948,807. The company has a 50 day simple moving average of $102.02 and a two-hundred day simple moving average of $107.75. The firm has a market cap of $25.61 billion, a P/E ratio of -31.33 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

Hedge Funds Weigh In On BioNTech

A number of hedge funds have recently bought and sold shares of BNTX. FMR LLC lifted its position in shares of BioNTech by 22.2% during the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares in the last quarter. Bank of New York Mellon Corp grew its position in BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after purchasing an additional 694,691 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in BioNTech in the 4th quarter valued at about $69,999,000. Invesco Ltd. lifted its position in shares of BioNTech by 643.7% during the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company's stock worth $58,747,000 after buying an additional 558,389 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of BioNTech by 632.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock worth $57,191,000 after buying an additional 433,388 shares during the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.